- |||||||||| Avastin (bevacizumab) / Roche
Biomarker, Journal, Tumor microenvironment, Metastases: Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer. (Pubmed Central) - Mar 30, 2023 They were classified as follows: patients who had not received preoperative treatment (UPFRONT group, n?=?54), who had received FOLFOX as preoperative chemotherapy (FOLFOX group, n?=?55), and who had undergone resection after combination FOLFOX and bevacizumab as unresectable colorectal cancer (B-MAB group, n?=?26)...In the B-MAB group, the numbers of PD-1 cells in the ST, FOXP3 lymphocytes in both areas, and CD163monocytes in the ST was lower than that in the other two groups, and a correlation with the histological therapeutic effect was observed. In advanced colorectal cancer, VEGF inhibitors may decrease the number of PD-1 cells and inhibit the infiltration of FOXP3 lymphocytes and CD163monocytes into the tumor environment.
- |||||||||| leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Mar 28, 2023 P2, N=80, Active, not recruiting, Also, digital PET/CT was found to detect occult metastatic disease not visualized on ceCT, that would have resulted in altered disease staging and therapeutic strategy in a substantial proportion of patients. Trial completion date: Jan 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2025
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: NCI-2018-02122: Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin (clinicaltrials.gov) - Mar 27, 2023 P2, N=11, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=37 --> 11 | Trial primary completion date: Jun 2026 --> Oct 2022
- |||||||||| Avastin (bevacizumab) / Roche
Innumerable Cavitary Lung Metastasis From Colorectal Cancer (Walter E. Washington Convention Center, Area J, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_8749; Patient started on FOLFIRI in addition to Bevacizumab...Multiple excavated nodules are very rarely reported with colon cancer. In one case series cavitation of lung metastasis has been reported in about 20% of patients being treated with Bevacizumab and was reported to carry better prognosis.
- |||||||||| Malignant Osteosarcoma, an Uncommon Cause of a Pulmonary Mass in an 18-year-old (Walter E. Washington Convention Center, Area J, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_8730;
Chemotherapeutics including doxorubicin, cisplatin, high-dose methotrexate with leucovorin, and ifosfamide are currently being used in the treatment of OS...Whereas, patients with metastases have a 20% 5-year survival rate.Teaching Point:Lung masses are rare in young adults. However while uncommon, osteosarcoma should still be considered by clinicians in the appropriate clinical setting.
- |||||||||| leucovorin calcium / Generic mfg., pyrimethamine / Generic mfg., atovaquone / Generic mfg.
Pulmonary Toxoplasmosis Diagnosed With Metagenomics (Walter E. Washington Convention Center, Area C, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_8447; Blood metagenomics targets microbial cell-free DNA from > 1200 pathogens with a reported sensitivity and specificity of 93.7% and 40.0%. This aided our diagnosis, confirmed with PCR and serology.
- |||||||||| A Rare Case of Herpes Simplex Virus Type1 Induced Hemophagocytic Lymphohistiocytosis in Adult Patient (Walter E. Washington Convention Center, Area A, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_7993;
We present an additional case of HSV-1 as an etiology of HLH.Case description: 66-year-old male with a past medical history of gastric adenocarcinoma status post total gastrectomy, on fluorouracil, leucovorin, oxaliplatin, docetaxel and trastuszumab recent diagnosis of typhilitis treated with levofloxacin and metronidazole presented with abdominal pain, diarrhea, and poor intake...He was started on antibiotics which included cefepime, vancomycin, and doxycycline...The patient was started on IV acyclovir and continuous renal replacement therapy given continued decompensation of renal function...Treatment would consist of etoposide, dexamethasone or methotrexate in addition to supportive care via blood product transfusions and treatment of underlying etiology. Literature review showed mostly pediatric case reports of HSV-1 induced HLH but rarely was it described in the adult population.
- |||||||||| methotrexate / Generic mfg.
Methotrexate Toxicity in CNS Lymphoma (Walter E. Washington Convention Center, Area I, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6624; It was noted that leucovorin was not provided during her time in the hospital, which may have helped improve the persistent myelosuppression. Lastly, hemodialysis upon admission could have also facilitated the clearance of MTX, helping reduce the risk of toxicity.
- |||||||||| methotrexate / Generic mfg.
Fatal Case of Methotrexate Toxicity Presenting With Severe Myelosuppression and Punctate Cutaneous Eruption of the Skin Flexures (Walter E. Washington Convention Center, Area I, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6620; Her medical regimen included furosemide, hydrochlorothiazide, levothyroxine, methotrexate, metoprolol succinate, and atorvastatin...Patient was treated with Leucovorin, intravenous fluids, Intravenous antibiotics, Filgrastim and wound care...This case illustrates why reviewing home medications and catching subtle cues can lead to faster diagnostic tests, treatment, and better outcomes. Her sepsis was addressed and treated immediately with broad spectrum antibiotics, however it was not enough to prevent further decompensation due to her ongoing myelosuppression and active infection.
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Second Look Laparoscopy in Colorectal Cancer (clinicaltrials.gov) - Mar 24, 2023 P2, N=140, Recruiting, Trial completion date: Apr 2028 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jul 2026 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
AGGRESSIVE MANAGEMENT OF ELDERLY PATIENTS WITH NON-METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (S505 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_7241; Conclusions Older patients with non-metastatic PDAC initiated on FOLFIRINOX with curative-intent experienced more toxicity-related emergency room visits and inpatient admissions and were less likely to complete their chemotherapy cycles when compared to younger patients. However, they were just as likely to undergo surgical exploration and resection and had similar adjusted survival outcomes when compared to younger patients, highlighting the feasibility of aggressive management of PDAC in elderly patients, including the use of neoadjuvant FOLFIRINOX.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
COMPLETE RESPONSE TO IMMUNOTHERAPY FOR MMR-DEFICIENT RECURRENT COLON CANCER: A CASE REPORT (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_6713; Main reasons for chemotherapy omission were postoperative failure-to-thrive (39%), baseline comorbidities (20%), and physician We report a case of a rapidly enlarging MMR-deficient recurrent colon cancer that responded well to immunotherapy, radiation and surgical resection with no evidence of recurrence for 4 years to date.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
LEVERAGING ENDOSCOPIC FINE NEEDLE BIOPSIES TO PERFORM LONGITUDINAL PROFILING OF PANCREATIC TUMORS (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_4309; Utilizing matched biospecimens from the same patient allows for a more controlled study of how compartment-specific alterations in the tumor contribute to the pathogenesis of pancreatic cancer on a patient-specific level. Our preliminary results support utilization of transcriptomic analysis of matched longitudinal pre- and post-treatment tumor tissue in PDAC patients for a comprehensive study of how the tumor microenvironment for an individual patient adapts over time in response to chemotherapy, with the ultimate goal of developing robust precision medicine tools in this deadly disease.
- |||||||||| PROLACTIN SIGNALING INDUCES GLUTAMINE METABOLISM IN PANCREATIC CANCER (S106 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_3696;
Current chemotherapeutic strategies are highly aggressive, involving combinations of gemcitabine, Abraxane, and FOLFIRINOX, which are often associated with significant adverse toxicities...Inhibition of PRLR signaling, either by genetic or pharmacologic approaches, suppressed glutamine gene expression and metabolite production, which was further associated with the observed decrease in PDAC cell proliferation and migration. Taken together, these data demonstrate the rationale for therapeutic targeting PRLR for PDAC.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
WHAT PREDICTS COMPLETE RESPONSE TO TNT IN LOCALLY ADVANCED RECTAL CANCER? (S504 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_3566; In this cohort of locally advanced rectal cancer patients, TNT achieved 36.9% CR.Absence of EMVI was the only independent predictor of CR at the time of diagnosis. Following TNT,endoscopy is a better predictor of CR than MRI.
|